# EDGAR Filing Document

**Accession Number:** 0001986247
**File Stem:** 0001213900-26-016382
**Filing Date:** 2026-2
**Character Count:** 4817
**Document Hash:** 8aaffb5708302d0b58114d8eed801bdb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-016382.hdr.sgml**: 20260213

**ACCESSION NUMBER**: 0001213900-26-016382

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260213

**FILED AS OF DATE**: 20260213

**DATE AS OF CHANGE**: 20260213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Park Ha Biological Technology Co., Ltd.
- **CENTRAL INDEX KEY:** 0001986247
- **STANDARD INDUSTRIAL CLASSIFICATION:** SOAP, DETERGENT, CLEANING PREPARATIONS, PERFUMES, COSMETICS [2840]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** F4
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42453
- **FILM NUMBER:** 26632293

**BUSINESS ADDRESS:**
- **STREET 1:** NO. 50 XIUXI ROAD
- **STREET 2:** 14F, BUILDING 3
- **CITY:** WUXI CITY
- **STATE:** F4
- **ZIP:** 214135
- **BUSINESS PHONE:** 864000127562

**MAIL ADDRESS:**
- **STREET 1:** NO. 50 XIUXI ROAD
- **STREET 2:** 14F, BUILDING 3
- **CITY:** WUXI CITY
- **STATE:** F4
- **ZIP:** 214135

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br> UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of February 2026

Commission File No. 001-42453

**PARK HA BIOLOGICAL TECHNOLOGY CO., LTD.**

(Translation of registrant's name into English)

**901, Building C<br> Phase 2, Wuxi International Life Science Innovation Campus<br> 196 Jinghui East Road<br> Xinwu District, Wuxi, Jiangsu Province<br> People's Republic of China 214000**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

**Disclosure of Share Capital in Connection with Proposed Reverse Stock Split**

Reference is made to the Form 6-K filed by Park Ha Biological Technology Co., Ltd. (the "Company") on February 9, 2026, announcing the Company's intention to effect a 1-for-50 reverse stock split (the "Reverse Split") of its Class A and Class B ordinary shares, which has been approved and authorized by a majority of the shareholders at an extraordinary meeting of shareholders held on December 26, 2025, and the Board of Directors of the Company subsequently approved the reverse stock split and the exact ratio of the reverse stock split on January 29, 2026.

The Company is providing the following disclosure regarding its issued and outstanding share capital prior to and following the proposed Reverse Split.

**Proposed Timing of the Reverse Split**

Subject to the Company's satisfaction of Nasdaq Operations notice requirements, the Company expects the Reverse Split to become effective on February 20, 2026, with trading to begin on a split-adjusted basis at the market open on that day.

**Pre-Reverse Split Issued and Outstanding Share Capital**

As of the date of this Report, and immediately prior to the effectiveness of the Reverse Split, the Company's total issued and outstanding share capital consists of 104,768,362 ordinary shares, comprised of:

**●** 85,718,362 Class A ordinary shares (par value US$0.00002 each, with 1 vote per share); and

● 19,050,000 Class B ordinary shares (par value US$0.00002 each, with 20 votes per share).

This share count reflects the cumulative impact of (i) the Company's best-efforts follow-on public offering of units, which closed on January 28, 2026, and (ii) subsequent cashless exercises of warrants issued in that offering.

**Post-Reverse Split Issued and Outstanding Share Capital**

Upon the effectiveness of the Reverse Split, the Company's issued and outstanding share capital is expected to be adjusted to 2,095,368 ordinary shares, comprised of:

● 1,714,368 Class A ordinary shares (par value US$0.001 each, with 1 vote per share); and

● 381,000 Class B ordinary shares (par value US$0.001 each, with 20 votes per share).

No fractional shares will be issued in connection with the Reverse Split. All fractional shares resulting from the Reverse Split will be rounded up to the nearest whole share.

No other material changes to the terms of the Company's securities are anticipated in connection with the Reverse Split.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 13, 2026

---

| | |
|:---|:---|
| Park Ha Biological Technology Co., Ltd. | Park Ha Biological Technology Co., Ltd. |
| By: | */s/ Xiaoqiu Zhang* |
| Name: | Xiaoqiu Zhang |
| Title: | Chief Executive Officer and<br> Chairperson of the Board |

---